Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

A phase 2 study of SR-8541A in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer (MSS-CRC).

Alexis S. Weston, Monil Shah, Rend Williams et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15602

e15602 Background: The five-year survival rate for colorectal cancer (CRC) remains at 14% despite improvements in early detection and the development of n...

Efficacy and safety of nivolumab plus chemotherapy versus chemotherapy alone for the treatment of advance non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.

Aizaz Ali, Malik Sheheryar, Waqas Inayat et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20576

e20576 Background: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. While chemotherapy remains a cornerstone f...

Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer (aNSCLC).

Amin Nassar, Candice Francheska Tambaoan, Hanna Tukachinsky et al. Jun 01, 2025 pp. 8628-8628 10.1200/jco.2025.43.16_suppl.8628

8628 Background: There is a critical gap in our understanding of the correlation between ctDNA driver VAF and outcomes in patients (pts) with aNSCLC treat...

Engaging community to co-design multilevel intervention to reduce lung cancer disparities in persistent poverty tracts through group model building and simulation.

Carmen Lee, Emily Hayes Wood, Arleana Waller et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22515

e22515 Background: In California, 13.9% were screened for lung cancer and 14.8% of men survived five years post-diagnosis (1988-2012) with over 80% of cas...

Investigating the association between breast cancer and coronary artery disease: Insights from a national cohort study.

Omar Obeidat, Jowan Al-Nusair, Mohammed Al-Nusair et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24016

e24016 Background: Exploring the risk of coronary artery disease (CAD) in breast cancer patients is important due to the growing number of breast cancer s...

Ripretinib versus sunitinib in imatinib-resistant gastro-intestinal stromal tumor with KIT Exon 11 mutations: A systematic review and meta-analysis.

Sandeep Guntuku, Sripada Preetham Kasire, Krishna Doshi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23518

e23518 Background: Gastrointestinal Stromal Tumor(GIST) is the most common GI tract sarcoma, with imatinib serving as the standard first-line therapy. How...

FHINCH study: Fertility and sexual health effects of cancer therapy in young women with lung cancer and melanoma.

Narjust Florez, Lauren Kiel, Rebekah Kaufman et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20081

e20081 Background: Recent clinical trials support the efficacy of neoadjuvant and adjuvant immune checkpoint inhibitors (ICIs) or tyrosine kinase inhibito...

Allogeneic hematopoietic stem cell transplantation in elderly patients (age over 70 years) with high grade myelodysplasia or high risk acute myeloid leukemia.

Ravjot Virdi, Jacob D. Bitran Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18547

e18547 Background: Elderly patients (over the age of 65 years) treated with allogeneic hematopoietic stem cell transplants (AHSCT) tend to do poorly with...

Updated results from a multicenter, single-arm phase II study of surufatinib plus sintilimab and IBI310 in patients with high-grade advanced-neuroendocrine neoplasm (HG-NEN).

Panpan Zhang, Yakun Wang, Jie Li et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16342

e16342 Background: HG-NEN are highly aggressive and associated with poor prognosis. Surufatinib (SUR), a selective inhibitor of VEGFRs, FGFR1, and CSF-1R,...

Investigating the determinants of immunotherapy response in the primary tumor of clear cell renal cell carcinoma (RCC).

Cerise Tang, Deepak Poduval, Suzanna Lee et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16507

e16507 Background: While previous studies have examined the determinants of a patient’s overall response to immune checkpoint inhibitor (ICI) in advanced...

Using a patient registry and novel follow-up protocol to impact identification, treatment, and adherence rates in HR+, HER2- early breast cancer patients at UF Health.

Kadrin Wilfong, Karen Colleen Daily, Eric Rosenberg et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23225

e23225 Background: High recurrence risk remains a challenge in HR+, HER2- early breast cancer (EBC). Outcomes have improved with intensified adjuvant endo...

Efficacy of immune checkpoint inhibitors in smokers vs non-smokers: A large real-world retrospective cohort analysis.

Nanda Siva, Shanawar Ali Waris, Adnan Saifuddin et al. Jun 01, 2025 pp. 11065-11065 10.1200/jco.2025.43.16_suppl.11065

11065 Background: Immune checkpoint inhibitors (ICIs) play a critical role in strengthening the immune response against tumors. Prior literature has shown...

Machine learning–based classification of cancer types using genomic profiling data from the Australian Molecular Screening and Therapeutics (MoST) program.

Frank Po-Yen Lin, Min Li Huang, John P. Grady et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13683

e13683 Background: Mutational patterns offer diagnostic value for cancer type determination, particularly in patients with cancer of unknown primary site...

An observational study on the usage of GLP-1 in breast cancer patients in the US.

Federico Gallo, Elsa Ng Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13107

e13107 Background: Recent approvals of Glucagon-Like Peptide-1 (GLP-1) for weight loss have demonstrated their clinical benefit beyond Type 2 Diabetes (T2...

Trends in second primary cancer incidence by primary colorectal cancer location.

Anand Shah, Pranav Gwalani, Shivani Modi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15707

e15707 Background: Patients with primary colorectal cancer (CRC) are at an increased risk of developing a second primary cancer (SPC) at any site. In the...

A phase I/Ib study of olaparib and ASTX727 in BRCA 1/2- and HRD-mutated tumors.

Pamela N. Munster, Robin Kate Kelley, Susan Calabrese et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps3183

TPS3183 Background: Patients with germline or somatic HRR pathway mutations often develop resistance despite initial response. Overlapping toxicities hind...

Neoadjuvant serplulimab in combination with chemotherapy for locally advanced gastric or gastro-esophageal junction cancer.

Hongjie Zhan, Liang Liu, Weilin Sun et al. Jun 01, 2025 pp. 4030-4030 10.1200/jco.2025.43.16_suppl.4030

4030 Background: Perioperative therapy combined with surgery is the standard treatment for locally advanced gastric or gastro-esophageal junction (G/GEJ)...

Genetic testing of an unselected gastric cancer cohort: Uncovering germline mutations and their clinical implications.

Mafalda Sousa, Teresa Duarte, Ines Oliveira et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22602

e22602 Background: Gastric cancer (GC) is the fifth most common cancer in Portugal and the third leading cause of cancer death worldwide. While most GC ca...

Bolstering access to clinical trials: Sociodemographic characteristics of patients enrolled in interventional clinical trials within a large, NCORP-designated community oncology practice setting.

Meera Vimala Ragavan, Shiyun Zhu, Sabrina Kailu Zhong et al. Jun 01, 2025 pp. 1523-1523 10.1200/jco.2025.43.16_suppl.1523

1523 Background: Access to clinical trials is an important aspect of cancer care given rapidly changing treatment paradigms.Most patients with cancer incl...

Exploring the “obesity paradox” in triple negative breast cancer patients receiving neoadjuvant immunotherapy.

Ashley Brooke Schreier, Aaron N. Holmes, Steven Chen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14664

e14664 Background: Despite being one of the most aggressive subtypes of breast cancer, triple-negative breast cancer (TNBC) is also the most immunogenic,...

Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.

Frank Po-Yen Lin, David Goldstein, John P. Grady et al. Jun 01, 2025 pp. 4120-4120 10.1200/jco.2025.43.16_suppl.4120

4120 Background: The genomic and prognostic characteristics of recurrent (R, from curative surgery) v de novo (D) presentation in...

Incidence of viral and non-viral etiologies of hepatocellular carcinoma (HCC) in the US over time by race and ethnicity.

Mona Cai, Kathleen Hurwitz, Kayla Hendrickson et al. Jun 01, 2025 pp. 10551-10551 10.1200/jco.2025.43.16_suppl.10551

10551 Background: HCC has an incidence of 5–6 cases per person-yr in the US, with varying rates among different racial and ethnic groups. While viral HCC...

Integration of a virtual personalized medicine review board integration into a major community oncology phase 1 unit.

Marilyn Elaine Hammer, Ben C. Coleman, Carissa Jones et al. Jun 01, 2025 pp. 11098-11098 10.1200/jco.2025.43.16_suppl.11098

11098 Background: Inclusion criteria for participating in oncology clinical trials have grown more complex, often challenging the enrollment process. Our...

Demographic characteristics of inflammatory bowel disease patients in Saudi Arabia and their relation to gastrointestinal cancers: An observational, prospective cohort study.

Abdelrahman Hassanein, Mahmoud Mosli, Faisal Batwa et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15691

e15691 Background: Inflammatory Bowel Diseases (IBD), including Crohn’s disease (CD), ulcerative colitis (UC), and fistulizing CD (FCD), are chronic condi...

MVP CAN model: Accelerating cancer diagnosis for underserved inpatients to bridge health gaps.

Peter Rakita, Brianna Graham, Rachel Rubin et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13546

e13546 Background: Temple University Hospital-Main Campus (TUH) of TU health system (TUHS) is in North Philadelphia, Pennsylvania (USA) where 40% of resid...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page